VFA
OMED

Virtus Fund Advisers’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Virtus Fund Advisers’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,078
Closed -$25K – 2784
2014
Q2 		$25K Buy
+1,078
New +$26.6K ﹤0.01% 2322

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Fund Advisers's OMED Position: Q3 2014 in Review

Virtus Fund Advisers sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2014, closing a stake of 1,078 shares — an estimated $25K sold.

Virtus Fund Advisers first reported a position in OMED in Q2 2014 and held it in 1 quarter. The position peaked at $25K in Q2 2014. 62 funds tracked by Wall St. Rank hold OMED as of Q3 2014.

  • Virtus Fund Advisers reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,078 OncoMed Pharmaceuticals, Inc. shares in Q3 2014, an estimated $25K.
  • Virtus Fund Advisers first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's OncoMed Pharmaceuticals, Inc. position peaked at $25K in Q2 2014.
  • 62 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.